Abstract 101P
Background
The proven success of combined CDK4/6 inhibitor (CDK4/6i) and endocrine therapy in estrogen receptor-positive (ER+) metastatic breast cancer has prompted evaluation of this therapeutic approach in patients with early-stage disease. Notably, the CDK4/6i abemaciclib and ribociclib, but not palbociclib, improved invasive disease-free survival in the adjuvant setting in clinical trials. These data suggest that complex assessment of breast tumor genomic, clinical and pathological characteristics, and CDK4/6i efficacy and toxicity profiles, will be required for a better refinement of indication for specific CDK4/6i in the early-stage setting. In the present study, we aimed to identify and characterize the early breast cancer patient population that will benefit the most from each CDK4/6i by using patient-derived breast cancer organoids.
Methods
We developed a repository of patient-derived organoids (PDOs) from ER+ primary breast tumor resections. RNA, DNA, and protein were purified from PDOs and paired fresh frozen tissue, for validation of organoids characteristics compared to the original tumor. To fully characterize our PDOs, we performed RNA sequencing (RNAseq), single nucleotide polymorphism/copy number variation (SNP/CNV) array, live-cell imaging, quantitative real-time PCR, and drug testing. Efficacy of CDK4/6i on selected PDOs was evaluated by viability and cytotoxicity assays, and gene expression profile in sensitive vs. resistant PDOs was compared by RNAseq.
Results
We found that various PDOs retained the main alterations of the original tumor, by SNP/CNV arrays. Furthermore, we were able to rank the organoids based on the response (IC50) to abemaciclib. By RNAseq and RT-qPCR we identified specific genes that might be linked with differential responses to CDK4/6i. Among these, we found concomitant CDK6 overexpression and, surprisingly, cyclin D1 downregulation in PDOs with higher IC50 towards CDK4/6i in both innate and acquired resistance models.
Conclusions
Our data suggest that high-CDK6 and low-cyclin D1 expression might be a biomarker for selection of patients with poor response to CDK4/6i abemaciclib in the adjuvant setting.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Ethics Committee of the Region of Southern Denmark and Copenhagen and Frederiksberg Counties; Danish Data Protection Agency and the Danish Breast Cancer Cooperative Group.
Funding
Danish Cancer Society; Sygeforsikring Danmark; Danmarks 3R-Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract